Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blocking stress hormones may reveal why overeating leads to fat gain

NCT ID NCT06556277

Knowledge-focused Sponsor: Eleonora Seelig Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether stress hormones (glucocorticoids) released after eating contribute to fat gain in overweight people. Twenty-three overweight men were given either a drug combination that blocks these hormones or a placebo while overeating for a week. Researchers measured changes in body fat to understand the hormone's role.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metyrapone and hydrocortisone
What this could lead to
If successful, this could help explain why some people gain fat when overeating, potentially pointing to new ways to prevent obesity.
What could go wrong
This is a small, early-stage study with only 23 participants, so results may not apply to everyone. It is designed to understand biology, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

23 people

The number who actually took part.

Started

Sep 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males aged 18 to 50 years * BMI≥ 25 kg/m² with a stable weight within past three months before study initiation Exclusion Criteria: * Any severe acute or chronic disease, including diabetes mellitus type 2 * Intake of GLP-1 agonists or hormone therapy * Hypercortisolism * Casual smoking (more than 6 cigarettes per day) * Frequent, heavy alcohol consumption (more than 30g/day) * Frequent, heavy caffeine consumption (more than 4 caffeinated drinks/day) * Regular physical exercise (more than 4hrs per week) * Shift work * Participation in an investigational drug trial within the past two months * Intake of any steroid-containing drugs, including topical steroids and inhalers, within 4 weeks of the study initiation * Known allergy to metyrapone * Inability or unwillingness to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glucocorticoids are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperphagia Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glucocorticoids Overeating Overweight and obesity

Contacts and locations

Locations

  • University Hospital Basel

    Basel, Canton of Basel-City, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.